In 2015, there will be an estimated 11.3 million cancer survivors. With an increasing
population of cancer survivors, it is imperative to understand the treatment options available …

BACKGROUND: Doxorubicin (D)(Adriamycin) is a potent and efficacious chemotherapeutic
agent in the treatment of various forms of cancer, but its use has been limited by the …

Aims Cardiac dysfunction is a severe complication of anthracycline‐containing anticancer
therapy. The outcome of anthracycline‐induced cardiomyopathy (AICM) compared with …

BACKGROUND: Although anthracycline therapy is invaluable for treating neoplastic
disorders, morbidity includes severe cardiomyopathy that leads to heart transplantation. This …

Anthracycline-induced cardiomyopathy: secrets and lies. - Abstract - Europe PMC Sign in |
Create an account https://orcid.org Europe PMC Menu About Tools Developers Help Contact us …

We aimed to determine whether malignancy after pediatric HT x for ACM affects overall post‐
HT x survival. Patients< 18y listed for HT x for ACM in the PHTS database between 1993 …

BACKGROUND: New anti-neoplastic drugs have improved survival of cancer patients but
have also been associated with chemotherapy-induced cardiomyopathy (CCMP), ultimately …

Objectives: The objective of this study was to determine the incidence of arrhythmias and
device (internal cardiac defibrillator/cardiac resynchronization therapy defibrillator) therapies …

Ongoing research into the mechanisms of anthracycline cardiotoxicity is warranted to allow
for the development of targeted preventive therapies. A consensus definition of …

Background. Anthracycline‐induced congestive heart failure (A‐CHF) is associated with
high reported incidence of morbidity and mortality. The long‐term clinical outcome of …